Odyssean LLC Buys 2,358 Shares of United Therapeutics Corporation $UTHR

Odyssean LLC grew its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 76.4% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 5,445 shares of the biotechnology company’s stock after buying an additional 2,358 shares during the quarter. Odyssean LLC’s holdings in United Therapeutics were worth $2,950,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of UTHR. Fiduciary Financial Advisors bought a new position in shares of United Therapeutics in the 2nd quarter valued at $30,000. Entrust Financial LLC bought a new stake in United Therapeutics during the 4th quarter worth $31,000. International Assets Investment Management LLC increased its holdings in United Therapeutics by 426.7% in the 1st quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 64 shares in the last quarter. Wilmington Savings Fund Society FSB increased its holdings in United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 49 shares in the last quarter. Finally, Elyxium Wealth LLC bought a new position in United Therapeutics in the fourth quarter valued at about $48,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently weighed in on UTHR. Weiss Ratings cut United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, August 27th. Bank of America dropped their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Morgan Stanley set a $515.00 target price on shares of United Therapeutics in a research report on Thursday, August 6th. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Finally, Royal Bank Of Canada reduced their target price on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $646.00.

Insider Activity

In other United Therapeutics news, CEO Martine A. Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $493.46, for a total value of $4,687,870.00. Following the transaction, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at approximately $160,099,642.78. The trade was a 2.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $482.03, for a total value of $4,000,849.00. Following the transaction, the executive vice president owned 45,172 shares in the company, valued at $21,774,259.16. The trade was a 15.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 404,075 shares of company stock worth $214,704,893. 8.60% of the stock is owned by corporate insiders.

Key Stories Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: The FDA accepted United Therapeutics’ supplemental new drug application for Tyvaso in idiopathic pulmonary fibrosis (IPF). The application is supported by Phase 3 TETON data showing improved lung function and reduced clinical worsening. FDA review is expected to conclude in April 2027, and approval could materially expand Tyvaso’s addressable market. FDA Accepts UTHR’s sNDA for Tyvaso in Idiopathic Pulmonary Fibrosis
• Neutral Sentiment: Analysts remain broadly constructive, with a consensus “Moderate Buy” rating and an average price target near $646. However, several firms have recently lowered their targets, indicating that optimism about UTHR’s pipeline and valuation is tempered by execution and growth concerns. Analyst Sentiment on United Therapeutics
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares for approximately $4.69 million, while EVP Paul Mahon sold 8,300 shares for about $4.00 million. Mahon’s sale reduced his holdings by 15.52%, and the transactions may be weighing on investor sentiment, even though the CEO’s sale was disclosed through an SEC filing and may have been prearranged. United Therapeutics Insider Selling
• Negative Sentiment: The latest quarterly results exceeded EPS expectations, but revenue of $783.3 million fell short of the $804.7 million consensus estimate and declined 1.9% year over year. The revenue weakness, combined with competition affecting pulmonary hypertension therapies, helps explain why investors remain cautious after earnings. United Therapeutics Earnings Performance

United Therapeutics Stock Down 0.5%

UTHR opened at $487.61 on Friday. United Therapeutics Corporation has a twelve month low of $375.61 and a twelve month high of $609.35. The company has a fifty day moving average of $525.95 and a 200-day moving average of $539.55. The stock has a market cap of $20.91 billion, a PE ratio of 17.45, a price-to-earnings-growth ratio of 2.45 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. During the same quarter in the prior year, the firm posted $6.41 earnings per share. The business’s quarterly revenue was down 1.9% compared to the same quarter last year. Sell-side analysts anticipate that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.